Finch Therapeutics Group Inc is a biotechnology business based in the US. Finch Therapeutics Group Inc shares (FNCH) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $12.55 – an increase of 0.4% over the previous week. Finch Therapeutics Group Inc employs 1 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $12.55 |
|---|---|
| 52-week range | $0.80 - $15.85 |
| 50-day moving average | $13.85 |
| 200-day moving average | $11.44 |
| Wall St. target price | $90.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-8.80 |
Historical closes compared with the close of $12.74 from 2025-05-02
| 1 week (2025-04-29) | 3.58% |
|---|---|
| 1 month (2025-04-07) | -3.19% |
| 3 months (2025-02-07) | 6.17% |
| 6 months (2024-11-07) | 10.78% |
| 1 year (2024-05-07) | 484.40% |
|---|---|
| 2 years (2023-05-05) | 9.59% |
| 3 years (2022-05-06) | 71.7 |
| 5 years (2020-05-03) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -21.89% |
| Return on equity TTM | -67.28% |
| Profit margin | 0% |
| Book value | $8.86 |
| Market Capitalization | $20.5 million |
TTM: trailing 12 months
We're not expecting Finch Therapeutics Group Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Finch Therapeutics Group Inc's shares were split on a 1:30 basis on 11 June 2023 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Finch Therapeutics Group Inc shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Finch Therapeutics Group Inc shares which in turn could have impacted Finch Therapeutics Group Inc's share price.
Over the last 12 months, Finch Therapeutics Group Inc's shares have ranged in value from as little as $0.8 up to $15.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Finch Therapeutics Group Inc's is 1.239. This would suggest that Finch Therapeutics Group Inc's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Finch Therapeutics Group Inc's beta into context you can compare it against those of similar companies.
Finch Therapeutics Group, Inc. , a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .